Skip to content
Menu

Agios Pharmaceuticals, Inc. AGIO

Full chart Compare
Set alert

Price alert · AGIO

All alert types
28.76 USD -0.92 (-3.10%)

Regular-session close

28.76 0.00 0.00%

After hours · Nov 19, 5:15 PM ET

28.71 Day range 30.35
23.00 52-week range 44.09
YTD
+5.66%
1 year
+28.74%

5D -0.69 (-2.21%)

313233TueWedThuFriMon30.50
Market cap
1.72B
Revenue (ttm)
140.84M
Profit margin
-264.76%
EPS (ttm)
-6.31
Shares out
59.81M
Forward P/E
-9.00
YTD return
+5.66%
1-year return
+28.74%
50-day average
32.86
200-day average
31.88
Volume
469.83K
Avg volume
1.06M
Open
29.93
Previous close
29.68
Day's range
28.71 – 30.35
52-week range
23.00 – 44.09
Beta
0.62
Analysts
Buy
Price target
46.11 (+60.3%)
Earnings date
Feb 11, 2027

Key statistics

Enterprise value
1.17B
Price / sales
12.21
Price / book
1.76
Revenue growth
330.00%
Free cash flow
-264.32M
Total cash
630.01M
Total debt
26.53M
Return on equity
-32.95%
Short % of float
11.02%

Fundamental scorecard

7 of 25 checks passed on AGIO’s reported financials

ValueGrowthProfitabilityHealthDividend

7of 25 checks passed

  • Value 1 of 5
  • Growth 2 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
AGIO Revenue — quarterly 55.38M
AGIO Net income — quarterly -65.05M
AGIO EPS — quarterly -1.09

Earnings

AGIO recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 11, 2027Dec 30, 2026-1.11———
Nov 5, 2026Sep 30, 2026-1.24-1.09+0.15+12.10%
Jul 30, 2026Jun 30, 2026-1.65-1.69-0.04-2.42%
Apr 29, 2026Mar 31, 2026-1.81-1.69+0.12+6.63%
Feb 12, 2026Dec 31, 2025-1.97-1.85+0.12+6.09%
Oct 30, 2025Sep 30, 2025-1.93-1.78+0.15+7.77%

Upgrades / downgrades

AGIO analyst upgrades and downgrades
DateFirmActionFromTo
Nov 6, 2026Truist SecuritiesmainBuyBuy
Nov 6, 2026HC Wainwright & Co.mainBuyBuy
Oct 7, 2026Truist SecuritiesmainBuyBuy
Sep 21, 2026B of A SecuritiesmainBuyBuy
Aug 7, 2026JP MorganmainNeutralNeutral
Jul 31, 2026CitigroupmainBuyBuy

About Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
agios.com

News

Your note

Sign in to keep a note on AGIO — it syncs with the Stock Master app.

Insider holders

AGIO insider holders
InsiderRelationLatest transactionDateShares held
ADAMS CATHERINE OWENDirectorConversion of Exercise of derivative securityJun 17, 202610,865
BACKSTROM JAY TDirectorStock Award(Grant)Jul 7, 20261,447
BALLAL RAHUL D.DirectorConversion of Exercise of derivative securityJun 17, 202615,230
CAPELLO JEFFREY DDirectorConversion of Exercise of derivative securityJun 17, 202610,865
FOSTER-CHEEK KAYE IDirectorConversion of Exercise of derivative securityJun 17, 202612,484
FOUSE JACQUALYN A.DirectorConversion of Exercise of derivative securityJun 17, 2026154,156

Institution ownership

AGIO institution ownership
Holder% heldSharesValueReported
Blackrock Inc.10.42%6,229,199179.15MSep 29, 2026
Farallon Capital Management LLC9.93%5,939,400170.82MSep 29, 2026
Shaw D.E. & Co., Inc.6.50%3,888,907111.84MSep 29, 2026
Morgan Stanley5.75%3,436,58998.84MSep 29, 2026
State Street Corporation5.46%3,264,65293.89MSep 29, 2026
Vanguard Portfolio Management LLC4.77%2,850,20481.97MSep 29, 2026

Fund ownership

AGIO fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.16%1,889,44754.34MJun 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF2.85%1,703,56448.99MSep 29, 2026
Delaware Group Equity Funds V-Nomura Small Cap Core Fund2.83%1,695,53348.76MAug 30, 2026
iShares Trust-iShares Russell 2000 ETF2.56%1,528,26443.95MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.28%1,362,73239.19MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund1.32%788,65522.68MJun 29, 2026